1
Richard Edward Armer, Graham Michael Wynne, Colin Richard Dorgan, Peter David Johnson: Compounds having CRTH2 antagonist activity. Oxagen, Sterne Kessler Goldstein & Fox PLLC, September 18, 2012: US08268878 (18 worldwide citation)

Compounds of general formula (I) wherein R is phenyl optionally substituted with one or more halo substituents; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma ...


2
Richard Edward Armer, Eric Roy Pettipher, Mark Whittaker, Graham Michael Wynne, Julia Vile, Frank Schroer: Compounds having CRTH2 antagonist activity. Oxagen, Sterne Kessler Goldstein & Fox P L L C, July 6, 2010: US07750027 (13 worldwide citation)

Compounds of general formula (I) wherein W is chloro or fluoro; R1 is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2 wherein eac ...


3
Richard Edward Armer, Graham Michael Wynne, Colin Richard Dorgan, Peter David Johnson: Compounds having CRTH2 antagonist activity. Oxagen, Sterne Kessler Goldstein & Fox P L L C, August 16, 2011: US07999119 (8 worldwide citation)

Compounds of general formula (I) wherein R is phenyl optionally substituted with one or more halo substituents; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma ...


4
Stuart Edward Bradley, John Kitchin, Graham Michael Wynne: Process for preparing resorcinol derivatives. Warner Lambert Company, J Michael Dixon, January 7, 2003: US06504037 (7 worldwide citation)

The present invention relates to an improved process for preparing 4-substituted resorcinol derivatives, and intermediate compounds useful in the preparation of such resorcinol derivatives.


5
Richard Edward Armer, Eric Roy Pettipher, Mark Whittaker, Graham Michael Wynne, Julia Vile, Frank Schroer: Compounds having CRTH2 antagonist activity. Atopix Therapeutics, Sterne Kessler Goldstein & Fox P L L C, October 22, 2013: US08563536 (6 worldwide citation)

Compounds of general formula (II) wherein W is chloro or fluoro; R1 is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2 wherein ea ...


6
Richard Edward Armer, Eric Roy Pettipher, Mark Whittaker, Graham Michael Wynne, Julia Vile, Frank Schroer: Compounds having CRTH2 antagonist activity. Oxagen, Sterne Kessler Goldstein & Fox P L L C, April 5, 2011: US07919512 (6 worldwide citation)

Compounds of general formula (II) wherein W is chloro or fluoro; R1 is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2 wherein ea ...


7
Richard Edward Armer, Carole Eliane Andree Maillol, Colin Richard Dorgan, Graham Michael Wynne, Julia Vile: Compounds having CRTH2 antagonist activity. Oxagen, Sterne Kessler Goldstein & Fox P L L C, May 1, 2012: US08168673 (5 worldwide citation)

Compounds of general formula (I) wherein W is chloro or fluoro; Z is a group SO2R1; wherein R1 is —C3-C8 cycloalkyl or heterocyclyl optionally substituted with one or more substituents chosen from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, ...


8

9
Richard Edward Armer, Eric Roy Pettipher, Mark Whittaker, Graham Michael Wynne, Julia Vile, Frank Schroer: Compounds having CRTH2 antagonist activity. Atopix Therapeutics, Sterne Kessler Goldstein & Fox P L L C, September 17, 2013: US08536158 (4 worldwide citation)

Compounds of general formula (I) wherein W is chloro or fluoro; R1 is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2 wherein eac ...


10